33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15823)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7078)
  4. Hematologic Malignancies, Division of (6211)
  5. Center for Hematologic Malignancies (6018)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4873)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15823)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7078)
  4. Hematologic Malignancies, Division of (6211)
  5. Center for Hematologic Malignancies (6018)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase III study (COSMIC-313) of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in patients (pts) with previously untreated advanced renal cell carcinoma (aRCC) of intermediate or poor risk
    Meeting Abstract

    Choueiri, T. K.; Albiges, L.; Powles, T.; Scheffold, C.; Wang, F.; Motzer, R. J.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Molecular characteristics of renal cell carcinoma (RCC) risk groups from JAVELIN Renal 101
    Meeting Abstract

    Choueiri, T. K.; Haanen, J. B. A. G.; Larkin, J. M. G.; Rini, B. I.; Albiges, L.; Motzer, R. J.; di Pietro, A.; Mu, X. J.; Ching, K. A.; Hariharan, S.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Fraction genome altered (FGA) to regulate both cell autonomous and non-cell autonomous functions in prostate cancer and its effect on prostate cancer aggressiveness
    Meeting Abstract

    Chakraborty, G.; Ghosh, A.; Nandakumar, S.; Armenia, J.; Mazzu, Y. Z.; Atiq, M. O.; Lee, G. S. M.; Mucci, L. A.; Merghoub, T.; Wolchok, J. D.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Marker lesion study of oral FGFR inhibitor BGJ398 in patients with FGFR3-altered intermediate-risk nonmuscle-invasive bladder cancer
    Meeting Abstract

    Cha, E. K.; Iyer, G.; Funt, S. A.; Regazzi, A. M.; Francis, J.; Heinemann, M. H.; Ostrovnaya, I.; Dalbagni, G.; Bajorin, D. F.; Bochner, B. H.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641)
    Meeting Abstract

    Chi, K. N.; Rathkopf, D. E.; Attard, G.; Smith, M. R.; Efstathiou, E.; Olmos, D.; Small, E. J.; Lee, J. Y.; Sieber, P. R.; Dunshee, C.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Prognostic factors in advanced seminoma: An analysis from the IGCCCG Update Consortium
    Meeting Abstract

    Beyer, J.; Collette, L.; Daugaard, G.; De Wit, R.; Tryakin, A.; Albany, C.; Stahl, O.; Fizazi, K.; Gietema, J. A.; De Giorgi, U.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Tumor protein expression of BRCA1 and development of lethal prostate cancer
    Meeting Abstract

    Ceraolo, C.; Gerke, T. A.; Zareba, P.; Pettersson, A.; Stopsack, K. H.; Chowdhury, D.; Ebot, E. M.; Flavin, R.; Finn, S. P.; Kantoff, P. W.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Analysis of clinical outcomes according to response status in prospective clinical trials of atezolizumab (atezo) in pretreated locally advanced/metastatic urothelial carcinoma (mUC)
    Meeting Abstract

    Bedke, J.; Merseburger, A. S.; Loriot, Y.; Castellano, D.; Choy, E.; Duran, I.; Rosenberg, J. E.; Petrylak, D. P.; Dreicer, R.; Perez-Gracia, J. L.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Association of circulating tumor cell chromosomal instability with worse outcomes in men with mCRPC treated with abiraterone or enzalutamide
    Meeting Abstract

    Brown, L. C.; Halabi, S.; Schonhoft, J.; Luo, J.; Nanus, D. M.; Giannakakou, P.; Szmulewitz, R. Z.; Danila, D. C.; Healy, P.; Anand, M.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A phase II study assessing the safety and efficacy of ASP1650 in male patients with incurable platinum refractory germ cell tumors
    Meeting Abstract

    Adra, N.; Vaughn, D. J.; Einhorn, L.; Hanna, N. H.; Rosales, M.; Arozullah, A.; Feldman, D. R.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save